GovWire

Guidance: Supply unlicensed medicinal products (specials)

Medicines Healthcare Products Regulatory Agency

May 12
09:34 2023

The supply of unlicensed medicinal products 'specials', MHRA guidance note 14

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need aversion of this document in a more accessible format, please email webupdates@mhra.gov.uk.Please tell us what format you need. It will help us if you say what assistive technology you use.

The supply of unlicensed cannabis-based products for medicinal use in humans

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need aversion of this document in a more accessible format, please email webupdates@mhra.gov.uk.Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This Medicines and Healthcare products Regulatory Agency (MHRA) guidance is for those who want to manufacture, import, distribute or supply unlicensed medicines for human use (also known as specials), including CBPMs

Specials are products which have been specially manufactured or imported for the treatment of an individual patient after being ordered by a:

  • doctor
  • dentist
  • nurse independent prescriber
  • pharmacist independent prescriber
  • supplementary prescriber

Persons authorised to procure unlicensed CBPMs in the UK are:

  • doctors on the GMC Specialist Register
  • specialist Importers with a Home Office import and Domestic licence and MHRA licence
  • registered pharmacies or retail pharmacy businesses (with Home Office Domestic licences, where appropriate)
  • licensed wholesale dealers for supply to the order of any of the above

We have published guidance for manufacturers specials licence holders on packing down medicines during the coronavirus (COVID-19) outbreak.

Published 6 May 2014
Last updated 12 May 2023 +show all updates
  1. Updated PDF for 'The supply of unlicensed medicinal products 'specials', MHRA guidance note 14'

  2. Updated to add guidance on manufacturing, importing, distributing and supplying specially manufactured or ordered cannabis-based products for medicinal use in humans (CBPMs) known as 'specials'.

  3. First published.

Related Articles

Comments

  1. We don't have any comments for this article yet. Why not join in and start a discussion.

Write a Comment

Your name:
Your email:
Comments:

Post my comment

Recent Comments

Follow Us on Twitter

Share This


Enjoyed this? Why not share it with others if you've found it useful by using one of the tools below: